Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

Analysts at StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report issued on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Up 5.5 %

Cumberland Pharmaceuticals stock opened at $1.53 on Friday. The stock has a market capitalization of $21.71 million, a PE ratio of -2.59 and a beta of 0.23. Cumberland Pharmaceuticals has a twelve month low of $1.38 and a twelve month high of $2.36. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $1.53 and a 200-day moving average of $1.77.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The company had revenue of $8.50 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 21.67% and a positive return on equity of 0.21%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.